-
FDA approves COVID-19 antiviral Xocova as PEP. But will it be accessible?
Shionogi, the Japanese company that makes Xocova (ensitrelvir), said the post-exposure prophylaxis drug will be available in mid-July in the U.S. and will have a list price of $1,400. But its impact will hinge on how easily people can access it, experts say. Read more…
Recent articles
Get the latest Long COVID news and commentary
Processing…
Success! You're on the list.
Whoops! There was an error and we couldn't process your subscription. Please reload the page and try again.
Check out our weekly podcast, Still Here
Spotify
Apple Podcasts
PocketCasts
iHeartRadio
RSS
Policy & Advocacy
-
“Not Recovered” protest for Long COVID, ME, and related diseases takes over The Hague
-
Alice Wong, disability activist and luminary, dies at 51
-
Long COVID advocacy is more than lobbying Congress: Here are some ways to get involved
-
As the American West faces increasing air pollution, protecting the right to mask is vital
-
Business school competition centers Long COVID and IACCs
-
It’s been a month. And we still don’t know much about Kennedy’s Long COVID consortium.
Science
Covid-19
Health
-
Winter Olympic athletes are rightfully taking COVID-19 precautions
-
Long COVID affects millions of children. The largest pediatric trial so far launches this year.
-
Metrodora promised comprehensive treatment. But within two years, it abruptly closed.
-
The CDC just sidelined these childhood vaccines. Here’s what they prevent.
-
Editor’s note: An update on a recent book excerpt
-
New AI tools are helping some people manage Long COVID
-
Between two crises: Living with Post-COVID Vaccine Syndrome in a Long COVID world
-
Video essay: How does Long COVID affect queer and trans communities?
-
Universities get an F on Long COVID. Here’s how they can support their students and reduce COVID-19 cases.
-
Even stones break in this heat: Experiencing Long COVID in Indonesia